Bli medlem
Bli medlem

Du är här


Orion Oyj: Publishing of Orion Corporation's Financial Statement Release for 2015 on 2 February 2016


Publishing of Orion Corporation's Financial Statement Release for 2015 on 2
February 2016

Orion will publish Financial Statement Release for 2015 on Tuesday, 2 February
2016 approximately at 12:00 noon Finnish time (EET). The release and related
presentation material in Finnish and in English will be available on the
Group's homepage after the publishing.

News conference for analysts and mediaA news conference for analysts and media will be held on Tuesday 2 February
2016 at 13:30 EET at Hotel Kämp,
address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will
give a brief presentation in English on the financial review. Questions can
be asked after the result presentation also via teleconference.

Participants should be prepared to present a photo ID on request.

Live webcast and conference callA link to the live webcast will be available at Orion's

The conference call ID is 7489965 and the phone numbers to participate the
conference are:

Finland: +358 (0)9 6937 9590
Sweden: +46 (0)8 5065 3936
UK: +44 (0)20 3427 1919
USA: +1 646 254 3362

News conference recordingsA recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on the Orion website later the
same day.

Silent periodThe silent period preceding the publication is ongoing and continues until the

Orion Corporation

| Timo Lappalainen Jari Karlson |
|President and CEO |
| CFO |
Contact person:

Tuukka Hirvonen, Communications Manager, IR&Financial Communications
tel. +358 10 426 2721


Orion Corporation
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical
ingredients and diagnostic tests. The company is continuously developing new
drugs and treatment methods. The core therapy areas of Orion's pharmaceutical
R&D are central nervous system (CNS) disorders, oncology and respiratory for
which Orion developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2014 amounted to EUR 1,015 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.